Ted Yednock

Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates.

Following IVT administration, ANX007 distributes to sites within the retina that are relevant to neurodegenerative ophthalmic disease with clear evidence of C1q target engagement.

Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma.

ANX007 intravitreal injections for glaucoma were well-tolerated and effectively engaged the C1q target, suggesting potential for monthly dosing. This supports further investigation in neurodegenerative eye diseases.